ARCT
Arcturus Therapeutics Holdings Inc.
Company Overview
| Mkt Cap | $219.43M | Price | $8.51 |
| Volume | 404.44K | Change | +0.00% |
| P/E Ratio | -2.7 | Open | $8.13 |
| Revenue | $152.3M | Prev Close | $8.51 |
| Net Income | $-80.9M | 52W Range | $5.85 - $24.17 |
| Div Yield | N/A | Target | $18.33 |
| Overall | 40 | Value | -- |
| Quality | -- | Technical | 40 |
No chart data available
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Latest News
Roth MKM Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ARCT | $8.51 | 0% | 404.44K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Arcturus Therapeutics Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW